Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate

被引：0

作者：

Emily A. Rosenthal

Pei-Shu Ho

Galen O. Joe

Sandra A. Mitchell

Susan Booher

Steven Z. Pavletic

Kristin Baird

Edward W. Cowen

Leora E. Comis

机构：

[1] National Institutes of Health,Rehabilitation Medicine Department, Clinical Center

[2] National Cancer Institute,Outcomes Research Branch, Division of Cancer Control and Population Sciences

[3] National Institutes of Health,Autoimmunity and Mucosal Immunology Branch, Division of Allergy, Immunology and Transplantation

[4] National Institute of Allergy and Infectious Diseases,Office of Tissues and Advanced Therapies

[5] National Institutes of Health,Dermatology Branch

[6] Center for Cancer Research,undefined

[7] National Cancer Institute,undefined

[8] National Institutes of Health,undefined

[9] Center for Biologics Evaluation and Research,undefined

[10] Food and Drug Administration,undefined

[11] National Institute of Arthritis and Musculoskeletal and Skin Diseases,undefined

[12] National Institutes of Health,undefined

来源：

Supportive Care in Cancer | 2020年 / 28卷

关键词：

Chronic graft-versus-host disease; Sclerosis; Functional impairment; Symptom burden; Health-related quality of life; Allogeneic hematopoietic stem cell transplantation;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：3679 / 3689

页数：10

共 456 条

[1]

Niederwieser D(2016)Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey Bone Marrow Transplant 51 778-785

[2]

Baldomero H(2007)Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study Blood 110 3784-3792

[3]

Szer J(2006)Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study Blood 108 2867-2873

[4]

Gratwohl M(2013)Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the Bone Marrow Transplantation Survivor Study Biol Blood Marrow Transplant 19 1073-1080

[5]

Aljurf M(2015)National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 Diagnosis and Staging Working Group report Biol Blood Marrow Transplant 21 389-401

[6]

Atsuta Y(2018)Patient-reported outcomes and health status associated with chronic graft-versus-host disease Haematologica 103 1535-1541

[7]

Bouzas LF(2011)Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium Haematologica 96 1528-1535

[8]

Confer D(2015)Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) Bone Marrow Transplant 50 253-258

[9]

Greinix H(2006)Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome Haematologica 91 258-261

[10]

Horowitz M(2014)Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 20 1751-1757

← 1 2 3 4 5 6 7 8 9 10 →